Regeneron Pharmaceuticals stock rally: Price targets to watch

Traders Union
All News
Stocks
Regeneron Pharmaceuticals jumps 2.99% today

Highlights

Regeneron Pharmaceuticals reported non-GAAP earnings of $14.29 per share and revenue of $4.29 billion for the second quarter of 2026, surpassing analyst estimates.
Shares of Regeneron face litigation risk related to class action lawsuits over disclosures connected to Phase 3 melanoma and Fianlimab-Libtayo studies.
Regeneron stock trades in a bullish pattern above key averages, with price expected in a $800.15 to $845.79 range, though overbought signals suggest potential for short-term consolidation.

Earnings beat drives buying despite litigation risks from melanoma drug

Regeneron Pharmaceuticals delivered strong second-quarter 2026 results, reporting non-GAAP earnings of $14.29 per share and revenue of $4.29 billion, both exceeding Wall Street expectations, according to Investing.com. This outperformance supports increased buying interest as investors reprice the stock based on demonstrated strength in core therapies. However, in the wake of these earnings, the company is facing class action lawsuits stemming from disclosures related to a Phase 3 melanoma therapy and alleged false statements about its Phase III Fianlimab-Libtayo Study, as noted by PR Newswire and GlobeNewswire. These legal developments introduce ongoing litigation risk that may temper some of the recent positive sentiment.

Mixed momentum signals as overbought conditions challenge support

On the technical front, REGN trades above the MA-20 and MA-50 on the hourly chart and remains well above the MA-200, highlighting underlying support from longer-term trends. The Ichimoku Kijun level at $800.54 serves as immediate support. Momentum signals are mixed, with RSI at 65.87 (Buy), ADX also signaling Buy, but both MACD and Awesome Oscillator remaining neutral. Oscillators including Stoch RSI, CCI, and Bull/Bear Power indicate the market is in overbought territory, with buyers dominating price action and short-term conditions stretched above typical ranges.

Upside bias as price consolidates within support and resistance

In the short term, the price is expected to consolidate between $800.15 and $845.79. There is a 73% probability of an upward move, making a decline less likely. The baseline scenario suggests trading continues within the current range between support at $800.54 and resistance near the upper bound. Should price break and hold above resistance, further upside momentum could develop, whereas any loss of the $800.54 support level may send REGN towards the lower end of the expected volatility band.

Viktoras Karapetjanc, expert at Traders Union, believes Regeneron’s strong Q2 2026 earnings are setting the macro and fundamental tone, attracting renewed investor interest. He sees sentiment remaining positive, supported by the robust results and clear upside bias despite emerging litigation risks. The analyst expects buyers to defend support near $800.54, with price action likely to consolidate before the next move. "I am constructive on REGN, as strong business performance outweighs litigation headwinds in the current market context."

Earlier, analysts noted that Regeneron Pharmaceuticals was exhibiting ongoing bullish momentum, underpinned by strong technicals and robust earnings, but cautioned that legal risks could temper further gains. The current analysis confirms this outlook, highlighting the importance of monitoring the $800.54 support level and resistance near $845.79 as key reference points for potential breakout or reversal scenarios.

Source of Data: REGN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.